Loading...
XETR
NXU
Market cap1.37bUSD
Apr 17, Last price  
69.80EUR
1D
0.14%
1Q
2.05%
Jan 2017
289.29%
Name

Nexus AG

Chart & Performance

D1W1MN
No data to show
P/E
39.01
P/S
4.60
EPS
1.79
Div Yield, %
0.32%
Shrs. gr., 5y
1.88%
Rev. gr., 5y
12.11%
Revenues
261m
+8.28%
20,983,00026,121,00029,712,00034,824,00040,363,00044,823,00053,534,00062,340,00073,263,00080,147,00097,269,000107,051,000119,083,000136,469,000147,648,000162,944,000188,178,000209,128,000241,459,000261,463,000
Net income
31m
+28.23%
262,000525,0001,163,0001,533,0002,103,0003,538,0004,695,0006,128,0007,601,0008,279,0007,583,0008,146,0009,832,00010,921,00010,841,00014,916,00017,153,00019,347,00024,031,00030,815,000
CFO
52m
+69.50%
5,620,0001,825,0002,528,0004,258,0007,313,00013,929,00010,995,0008,276,00010,544,00011,594,00018,145,00016,542,00021,677,00020,241,00024,618,00030,947,00031,386,00033,875,00030,407,00051,541,000
Dividend
May 23, 20250 EUR/sh
Earnings
May 12, 2025

Profile

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and KIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/REHAB for rehabilitation facilities; ITR, a software for rehabilitation, clinics, and hotels with medical care; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/QM for quality management; NEXUS/INTEGRATION SERVER, an interface management; NEXUS/CLOUD IT, outsourcing solution; NEXUS/EPS, a software solution to supplement SAP personnel management, as well as process and HR consulting in the SAP environment; ifa systems, an ophthalmology software solution; Sophrona solutions, ophthalmology patients and referral program; and NEXUS/DIS, interdisciplinary diagnostic information system. Its information systems also comprise NEXUS/SWISSLAB, a laboratory information system; NEXUS/LAURIS for order communication in diagnostics; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; dc-Pathos and dc-LabMan for pathology and cytology devices; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUs/CHILI, for PACS and teleradiology solutions; NEXUS/ASTRAIA for obstetrics and gynecology; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical specialist diagnostics and device integration; NEXUS/HOME for senior citizen and nursing homes; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/PAT, an administration system for hospitals; and osoTEC for billing personal and other services. In addition, the company offers SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS/EPD, NEXUS/AEMP, NEXUS/SPM, EuroSDS, RVS Software, NEXUS/VITA and TESIS VITA, and NEXUS/ESKULAP. NEXUS AG is headquartered in Donaueschingen, Germany.
URL
https://www.nexus-ag.de/
IPO date
Jul 24, 2000
Employees
1,700
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
261,463
8.28%
241,459
15.46%
209,128
11.13%
Cost of revenue
56,101
236,916
86,752
Unusual Expense (Income)
NOPBT
205,362
4,543
122,376
NOPBT Margin
78.54%
1.88%
58.52%
Operating Taxes
8,879
9,202
7,491
Tax Rate
4.32%
202.55%
6.12%
NOPAT
196,483
(4,659)
114,885
Net income
30,815
28.23%
24,031
24.21%
19,347
12.79%
Dividends
(3,798)
(3,620)
(3,153)
Dividend yield
Proceeds from repurchase of equity
(1,485)
(1,386)
71,120
BB yield
Debt
Debt current
5,279
4,807
4,358
Long-term debt
36,551
35,683
32,984
Deferred revenue
Other long-term liabilities
35,832
39,492
16,601
Net debt
22,318
(61,146)
17,274
Cash flow
Cash from operating activities
51,541
30,407
33,875
CAPEX
(10,388)
(9,457)
(5,575)
Cash from investing activities
(30,315)
(17,022)
(98,552)
Cash from financing activities
(19,628)
(16,722)
57,969
FCF
206,595
(10,932)
111,374
Balance
Cash
117,231
99,004
110,952
Long term investments
(97,719)
2,632
(90,884)
Excess cash
6,439
89,563
9,612
Stockholders' equity
179,483
156,074
133,254
Invested Capital
333,267
228,756
251,703
ROIC
69.92%
56.78%
ROCE
58.22%
1.38%
45.33%
EV
Common stock shares outstanding
17,263
17,249
16,006
Price
Market cap
EV
EBITDA
224,324
23,059
138,880
EV/EBITDA
Interest
2,423
1,919
1,037
Interest/NOPBT
1.18%
42.24%
0.85%